ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC)
today announced that Andrew Gengos, Chief Executive Officer of
ImmunoCellular, will present a corporate overview and business update at
the 25th Annual ROTH Conference on Monday, March 18, 2013 at
1:30 pm PT at the Ritz-Carlton, Laguna Niguel, CA.
To access the live audio webcast of the ROTH presentation, please log on
through a link located in the Investors section of ImmunoCellular's
website at www.imuc.com,
under the Events & Presentations tab. A replay of the webcast will be
available one hour after the conclusion of the live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage
company that is developing immune-based therapies for the treatment of
brain and other cancers. ImmunoCellular is conducting a Phase II trial
of its lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma.
ImmunoCellular’s pipeline also includes ICT-121, a dendritic cell
vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting
ovarian cancer antigens and cancer stem cells. To learn more about
ImmunoCellular, please visit www.imuc.com.
